Abstract
Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) often present with loco-regional disease; approximately 14% of patients present with metastatic disease. Despite aggressive primary therapy over 50% of newly diagnosed patients treated radically with either surgery and/or radiotherapy with/without chemotherapy will develop recurrent disease, with the majority of recurrences occurring locally. Standard therapy for these patients is a platinum-containing regime (PCCC) or PD-1 inhibitor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
